{
  "ticker": "LLY",
  "target_date": "2025-09-10",
  "actual_date": "2025-09-10",
  "collected_at": "2025-12-08T12:15:51.463313",
  "price": {
    "open": 746.99,
    "high": 754.69,
    "low": 741.4,
    "close": 753.5133666992188,
    "volume": 2477400,
    "change_1d_pct": 0.53,
    "change_7d_pct": 3.01,
    "change_30d_pct": -0.87
  },
  "technicals": {
    "rsi_14": 70.25,
    "sma_20": 718.37,
    "sma_50": 740.94,
    "macd": 4.47,
    "macd_signal": -1.801,
    "macd_histogram": 6.271,
    "bb_upper": 767.63,
    "bb_lower": 669.11,
    "price_vs_sma20_pct": 4.89,
    "price_vs_sma50_pct": 1.7,
    "volume_ratio": 0.57
  },
  "fundamentals": {
    "market_cap": 892575088640,
    "pe_ratio": 48.78344,
    "forward_pe": 43.93954,
    "price_to_book": 37.487576,
    "price_to_sales": 15.021509,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.46,
    "pct_from_52w_low": 59.62
  },
  "macro": {
    "spy": {
      "price": 650.41,
      "change_1d_pct": 0.29,
      "change_7d_pct": 1.86
    },
    "vix": {
      "level": 15.35,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.03
    },
    "dollar_index": {
      "level": 97.78
    },
    "gold": {
      "price": 3643.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Tracking Saudi Sovereign Wealth Fund's 13F Portfolio - Q2 2025 Update",
      "source": "SeekingAlpha",
      "datetime": 1757545741,
      "summary": "PIF\u00e2\u0080\u0099s US 13F portfolio value declined to $23.81B, with Uber, Electronic Arts, Lucid, Take-Two, and ARM comprising 77% of assets. See more insights here.",
      "url": "https://finnhub.io/api/news?id=22e6b64b4657d5735d1a63216963e8b9802f2f4188e3ef18569f68660cb7686c"
    },
    {
      "headline": "Hims & Hers Looks Like Hyper Growth At A Reasonable Price",
      "source": "SeekingAlpha",
      "datetime": 1757544722,
      "summary": "Hims & Hers' scalable model, product launches, and global expansion plans support its ambitious 2030 revenue and EBITDA targets. Read why HIMS stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=b347d0eae1acd3dc3ff822492b523fc3853dc74768ae7b9d3ab4dbac64d78ffa"
    },
    {
      "headline": "Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets",
      "source": "Yahoo",
      "datetime": 1757539867,
      "summary": "The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S\u2019 (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.\u2019s (NYSE:LLY) tirzepatide (Zepbound) for obesity management. ICER is ",
      "url": "https://finnhub.io/api/news?id=1c10768124faae1b3df70ae8b86fb35ce39e70be5f8a9947005263971e78a4c1"
    },
    {
      "headline": "Trump\u2019s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.",
      "source": "Yahoo",
      "datetime": 1757533740,
      "summary": "A new Trump administration crackdown on prescription drug ads directed at consumers could substantially drag on pharmaceutical revenues\u2014if it\u2019s successful at reining in the billions of dollars that drug companies spend on ads each year in the U.S.  It remains unclear what impact these government mea",
      "url": "https://finnhub.io/api/news?id=83781c4c6edbf9d5214a2a3bd1c314075e02f999ffa209003a3348c114a1f94d"
    },
    {
      "headline": "Rate of employers covering weight-loss drugs is flat, Cigna says",
      "source": "Yahoo",
      "datetime": 1757532763,
      "summary": "(Reuters) -Cigna said on Wednesday the percentage of employers paying for obesity drugs has remained flat year-over-year, though the health insurer still sees an uptick in demand for the wildly popular treatments.  More than 50% of its Evernorth unit's clients, a group that includes large employers ",
      "url": "https://finnhub.io/api/news?id=0f1164b9dd925462d2f21357cbdfbdf201295b2ad51dc15aae7816df07d0a6c7"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-08",
      "description": "xslF345X05/wk-form4_1757362781.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000238/xslF345X05/wk-form4_1757362781.xml"
    },
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412129.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000236/xslF345X05/wk-form4_1756412129.xml"
    },
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412046.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000234/xslF345X05/wk-form4_1756412046.xml"
    },
    {
      "form": "8-K",
      "date": "2025-08-20",
      "description": "d929636d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634987.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000232/xslF345X05/wk-form4_1755634987.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}